更新于：2024-06-29
Perindopril/Indapamide
培哚普利吲达帕胺
更新于：2024-06-29
概要
基本信息
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2005-09-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C35H48ClN5O8S |
InChIKeyLRRJSCKXFJTRLC-MHXJNQAMSA-N |
CAS号182176-83-6 |
关联
8
项与 培哚普利吲达帕胺 相关的临床试验培哚普利吲达帕胺片在健康受试者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后状态下生物等效性试验
Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India
培哚普利吲达帕胺片在中国健康受试者中进行的单中心、随机、开放、单次（空腹/餐后）、口服给药、两制剂、两序列、两周期、交叉的人体生物等效性试验
100 项与 培哚普利吲达帕胺 相关的临床结果
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的转化医学
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的专利（医药）
登录后查看更多信息
166
项与 培哚普利吲达帕胺 相关的文献（医药）2023-08-01The Journal of the Association of Physicians of India
ADVANCE to ADVANCE-ON: Unfolding the "Legacy Story" in Diabetes.
Article
作者: Kalra, Sanjay
Type 2 diabetes mellitus (T2DM) is a progressive disease. The importance of early intensive glucose lowering in preventing vascular complications in diabetes is well established. Sulfonylureas (SU) is recommended by most guidelines and widely used for the management of T2DM. However, there has been ambiguity around the long-term benefits with regard to microvascular and macrovascular outcomes with SUs. The United Kingdom Prospective Diabetes Study (UKPDS) provided evidence of sustained cardiovascular (CV) and microvascular benefits of previous intensive glycemic control with SUs or insulin in T2DM patients. The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release (MR) Controlled Evaluation (ADVANCE) trial, another landmark study in T2DM patients and its posttrial observational follow-up (FU) study [ADVANCE-Observational Study (ADVANCE-ON)] together provide definite evidence for sustained renal benefits of gliclazide MR based intensive glucose control initiated early during the course of diabetes. These effects, however, may be specific to gliclazide. Evidence from other studies and reviews also suggests that gliclazide MR may hold a distinct place among currently available SUs and reinforce its utility in diabetes management.
2023-03-01Hypertension (Dallas, Tex. : 1979)
Clinical Utility of Short-Term Blood Pressure Measures to Inform Long-Term Blood Pressure Management
Article
作者: Harrap, Stephen ; Poulter, Neil ; Rodgers, Anthony ; Chalmers, John ; Woodward, Mark ; Mancia, Giuseppe ; Wang, Nelson ; Harris, Katie
Background::
Decisions about hypertension management are substantially influenced by blood pressure (BP) levels measured before and soon after starting BP lowering drugs. We aimed to assess the utility of short-term BP changes in individuals in terms of long-term treatment response.
Methods::
Post hoc analyses of 2 randomized trials with 4-to-6 weeks active run-in for all participants, followed by randomization to active BP lowering treatment (combination perindopril±indapamide) or placebo. We categorized individuals by degree of systolic BP (SBP) change during active run-in treatment and assessed associations with subsequent postrandomization placebo-corrected BP reduction, cardiovascular events, and tolerability. We included individuals with baseline BP ≥140/90 mm Hg from the PROGRESS trial (Perindopril Protection Against Recurrent Stroke Study; 4275 individuals with cerebrovascular disease) and ADVANCE trial (The Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation; 6610 individuals with diabetes).
Results::
During the active run-in period, the proportion of participants with initial SBP changes in 4 categories (SBP increase, 0–9.9 mm Hg decrease, 10–19.9 mm Hg decrease, and ≥20 mm Hg decrease) were 17%, 27%, 28%, and 28% in PROGRESS and 21%, 22%, 24%, and 33% in ADVANCE. Randomization to active therapy achieved similar placebo-corrected long-term BP reductions across the 4 initial SBP change groups in both trials (
P
-values for heterogeneity >0.1). There was no significant difference in achieving BP <140/90 mm Hg at follow-up, major cardiovascular events, nor treatment tolerability according to the SBP change during active run-in period (all
P
-values >0.1).
Conclusions::
An individual’s apparent BP change immediately after commencing therapy has limited clinical utility. Therefore, more emphasis should be given to use of evidence-based regimens and measures over the long-term to ensure sustained BP control.
Registration::
URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT00145925.
2022-09-01Journal of the American College of Cardiology
Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes
Article
作者: Harrap, Stephen ; Poulter, Neil ; Mancia, Giuseppe ; Harris, Katie ; Wang, Nelson ; Woodward, Mark ; Chalmers, John ; Zoungas, Sophia ; Rodgers, Anthony ; Hamet, Pavel ; Williams, Bryan
BACKGROUND:
Standard measures of blood pressure (BP) do not account for both the magnitude and duration of exposure to elevated BP over time.
OBJECTIVES:
The purpose of this study was to assess the association between cumulative systolic blood pressure (SBP) load and risk of cardiovascular events in patients with type 2 diabetes.
METHODS:
A post hoc analysis of patients with type 2 diabetes followed by the ADVANCE-ON (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation - Observational Study). Cumulative SBP load was defined as the area under curve for SBP values ≥130 mm Hg divided by the area under curve for all measured SBP values over a 24-month exposure period. HRs for the association between cumulative SBP load with major cardiovascular events and death were estimated using Cox models.
RESULTS:
Over a median 7.6 years of follow-up, 1,469 major cardiovascular events, 1,615 deaths, and 660 cardiovascular deaths were observed in 9,338 participants. Each 1-SD increase in cumulative SBP load was associated with a 14% increase in major cardiovascular events (HR: 1.14; 95% CI: 1.09-1.20), 13% increase in all-cause mortality (HR: 1.13; 95% CI: 1.13-1.18), and 21% increase in cardiovascular death (HR: 1.21; 95% CI: 1.13-1.29). For the prediction of cardiovascular events and death, cumulative SBP load outperformed mean SBP, time-below-target SBP, and visit-to-visit SBP variability in terms of Akaike information criterion and net reclassification indexes.
CONCLUSIONS:
Cumulative SBP load may provide better prediction of major cardiovascular events compared with traditional BP measures among patients with type 2 diabetes. These findings reinforce the importance of both the magnitude and duration of exposure to elevated SBP in assessing cardiovascular risk. (Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study [ADVANCE-ON]; NCT00949286).
100 项与 培哚普利吲达帕胺 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 中国 | 2005-09-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 9,195 | 鹹艱築糧齋選築鹽鏇餘(壓淵積鬱鹹窪鏇遞膚顧): HR = 0.1 (95% CI, 0.01 ~ 0.79) | 积极 | 2015-11-03 | |||
临床3期 | 11,140 | (Normal cognitive function) | 淵醖艱蓋襯憲鹹鹹糧積(鬱願夢築構願襯願夢構): HR = 1.33 (95% CI, 1.16 ~ 1.54), P-Value = < 0.03 更多 | - | 2009-11-01 | ||
(Mild cognitive dysfunction) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用